130 related articles for article (PubMed ID: 12065636)
1. Spermine modulation of the glutamate(NMDA) receptor is differentially responsive to conantokins in normal and Alzheimer's disease human cerebral cortex.
Ragnarsson L; Mortensen M; Dodd PR; Lewis RJ
J Neurochem; 2002 May; 81(4):765-79. PubMed ID: 12065636
[TBL] [Abstract][Full Text] [Related]
2. The effects of alanine-substituted conantokin-G and ifenprodil on the human spermine-activated N-methyl-D-aspartate receptor.
Tsai VW; Dodd PR; Lewis RJ
Neuroscience; 2005; 130(2):457-64. PubMed ID: 15664702
[TBL] [Abstract][Full Text] [Related]
3. The modulatory effect of spermine on the glutamate-NMDA receptor is regionally variable in normal human adult cerebral cortex.
Mortensen M; Matsumoto I; Niwa S; Dodd PR
Pharmacol Toxicol; 1999 Mar; 84(3):135-42. PubMed ID: 10193675
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity studies of conantokins as human N-methyl-D-aspartate receptor modulators.
Nielsen KJ; Skjaerbaek N; Dooley M; Adams DA; Mortensen M; Dodd PR; Craik DJ; Alewood PF; Lewis RJ
J Med Chem; 1999 Feb; 42(3):415-26. PubMed ID: 9986713
[TBL] [Abstract][Full Text] [Related]
5. Preservation of redox, polyamine, and glycine modulatory domains of the N-methyl-D-aspartate receptor in Alzheimer's disease.
Palmer AM; Burns MA
J Neurochem; 1994 Jan; 62(1):187-96. PubMed ID: 8263519
[TBL] [Abstract][Full Text] [Related]
6. Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors.
Donevan SD; McCabe RT
Mol Pharmacol; 2000 Sep; 58(3):614-23. PubMed ID: 10953056
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of NMDA-induced currents by conantokin-G and conantokin-T in cultured embryonic murine hippocampal neurons.
Klein RC; Galdzicki Z; Castellino FJ
Neuropharmacology; 1999 Dec; 38(12):1819-29. PubMed ID: 10608277
[TBL] [Abstract][Full Text] [Related]
8. Structure-function relationships of the NMDA receptor antagonist peptide, conantokin-R.
Blandl T; Warder SE; Prorok M; Castellino FJ
FEBS Lett; 2000 Mar; 470(2):139-46. PubMed ID: 10734223
[TBL] [Abstract][Full Text] [Related]
9. Point mutations identify the glutamate binding pocket of the N-methyl-D-aspartate receptor as major site of conantokin-G inhibition.
Wittekindt B; Malany S; Schemm R; Otvos L; Maccecchini ML; Laube B; Betz H
Neuropharmacology; 2001 Nov; 41(6):753-61. PubMed ID: 11640930
[TBL] [Abstract][Full Text] [Related]
10. Developmental maturation of the N-methyl-D-aspartic acid receptor channel complex in postnatal rat brain.
Sircar R
Int J Dev Neurosci; 2000 Feb; 18(1):121-31. PubMed ID: 10708913
[TBL] [Abstract][Full Text] [Related]
11. Zinc and ifenprodil allosterically inhibit two separate polyamine-sensitive sites at N-methyl-D-aspartate receptor complex.
Berger ML; Rebernik P
J Pharmacol Exp Ther; 1999 Jun; 289(3):1584-91. PubMed ID: 10336556
[TBL] [Abstract][Full Text] [Related]
12. Direct binding properties of conantokins to native N-methyl-d-aspartate receptors.
Klein RC; Prorok M; Castellino FJ
J Pept Res; 2003 Jun; 61(6):307-17. PubMed ID: 12753378
[TBL] [Abstract][Full Text] [Related]
13. NMDA receptor subunit-dependent modulation by conantokin-G and Ala7-conantokin-G.
Ragnarsson L; Yasuda T; Lewis RJ; Dodd PR; Adams DJ
J Neurochem; 2006 Jan; 96(1):283-91. PubMed ID: 16336218
[TBL] [Abstract][Full Text] [Related]
14. Developmental changes in the sensitivity of the N-methyl-D-aspartate receptor to polyamines.
Williams K; Hanna JL; Molinoff PB
Mol Pharmacol; 1991 Nov; 40(5):774-82. PubMed ID: 1682796
[TBL] [Abstract][Full Text] [Related]
15. Polyamine and redox modulation of [3H]MK-801 binding to N-methyl-D-aspartate receptors in the spinal cord and cerebral cortex.
Sundström E; Mo LL
Pharmacol Toxicol; 2001 Jun; 88(6):342-8. PubMed ID: 11453375
[TBL] [Abstract][Full Text] [Related]
16. Synthetic analogues of conantokin-G: NMDA antagonists acting through a novel polyamine-coupled site.
Zhou LM; Szendrei GI; Fossom LH; Maccecchini ML; Skolnick P; Otvos L
J Neurochem; 1996 Feb; 66(2):620-8. PubMed ID: 8592132
[TBL] [Abstract][Full Text] [Related]
17. Kinetic and mechanistic characterization of NMDA receptor antagonism by replacement and truncation variants of the conantokin peptides.
Klein RC; Warder SE; Galdzicki Z; Castellino FJ; Prorok M
Neuropharmacology; 2001 Dec; 41(7):801-10. PubMed ID: 11684144
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus.
White HS; McCabe RT; Armstrong H; Donevan SD; Cruz LJ; Abogadie FC; Torres J; Rivier JE; Paarmann I; Hollmann M; Olivera BM
J Pharmacol Exp Ther; 2000 Jan; 292(1):425-32. PubMed ID: 10604979
[TBL] [Abstract][Full Text] [Related]
19. 123Iodo-MK-801: a spect agent for imaging the pattern and extent of glutamate (NMDA) receptor activation in Alzheimer's disease.
Brown DR; Wyper DJ; Owens J; Patterson J; Kelly RC; Hunter R; McCulloch J
J Psychiatr Res; 1997; 31(6):605-19. PubMed ID: 9447566
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of MK801 binding in adult rat brain sections by conantokin-G and conantokin-T.
Klein RC; Castellino FJ
Neurosci Lett; 1999 Oct; 273(3):171-4. PubMed ID: 10515186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
